HTG Molecular Diagnostics (NASDAQ:HTGM)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Thursday, February 1st. They presently have a $6.00 target price on the medical research company’s stock. HC Wainwright’s price objective points to a potential upside of 18.58% from the stock’s previous close.
HTGM has been the topic of a number of other research reports. ValuEngine raised HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a research note on Wednesday, January 10th. Finally, Canaccord Genuity boosted their price target on shares of HTG Molecular Diagnostics to $5.00 in a research note on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $5.31.
Shares of HTG Molecular Diagnostics (NASDAQ HTGM) opened at $5.06 on Thursday. The stock has a market capitalization of $131.45, a P/E ratio of -1.98 and a beta of 2.04. HTG Molecular Diagnostics has a 12-month low of $1.20 and a 12-month high of $13.25.
Large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of HTG Molecular Diagnostics by 38.9% in the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after acquiring an additional 37,841 shares in the last quarter. Granahan Investment Management Inc. MA grew its stake in shares of HTG Molecular Diagnostics by 488.3% during the third quarter. Granahan Investment Management Inc. MA now owns 416,608 shares of the medical research company’s stock worth $708,000 after purchasing an additional 345,798 shares in the last quarter. Finally, Private Wealth Partners LLC acquired a new position in shares of HTG Molecular Diagnostics during the fourth quarter worth $710,000. Institutional investors and hedge funds own 8.62% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2018/02/18/hc-wainwright-reiterates-buy-rating-for-htg-molecular-diagnostics-htgm.html.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.
Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.